Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mamta Parikh

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 19, 2021
Total-Body PET Multiparametric Imaging of Cancer Using a Voxelwise Strategy of Compartmental ModelingGuobao Wang, Lorenzo Nardo, Mamta Parikh, et al.
Scientific Reports|March 19, 2021
Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancerMamta Parikh, Chengfei Liu, Chun-Yi Wu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 28, 2024
High-Temporal-Resolution Kinetic Modeling of Lung Tumors with Dual-Blood Input Function Using Total-Body Dynamic PETYiran Wang, Yasser G Abdelhafez, Benjamin A Spencer, et al.
Cancer|June 19, 2026
Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparibRana R McKay, Wanling Xie, Archana Ajmera, et al.
Biomedicines|May 27, 2026
Characterizing Response to PARP Inhibitor Treatment Combinations in Advanced Prostate CancerBryan Correa Gonzalez, Akshaya Karthikeyan, Love A Moore, et al.
Prostate Cancer and Prostatic Diseases|February 29, 2024
Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronelPrimo N Lara, Edward Mayerson, Erik Gertz, et al.
Nanomedicine (London, England)|June 2, 2026
A Phase I trial of PLZ4-coated paclitaxel-loaded micelles in patients with refractory non-muscle-invasive bladder cancerAthira Narayan, Ryan C Leibrandt, Joyce S Lee, et al.
Endocrine-Related Cancer|May 1, 2025
Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancerAlyssa Liang, Shuchi Gulati, Quillan Huang, et al.
Scientific Reports|June 14, 2023
Cisplatin-induced increase in heregulin 1 and its attenuation by the monoclonal ErbB3 antibody seribantumab in bladder cancerThomas M Steele, Maria Malvina Tsamouri, Salma Siddiqui, et al.
Molecular Cancer Therapeutics|December 5, 2025
IGFBP3-SphK1/S1P Signaling Axis Drives Enzalutamide Resistance in Advanced Prostate CancerAmy R Leslie, Shu Ning, Masuda Sharifi, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 19, 2021
Total-Body PET Multiparametric Imaging of Cancer Using a Voxelwise Strategy of Compartmental ModelingGuobao Wang, Lorenzo Nardo, Mamta Parikh, et al.
Scientific Reports|March 19, 2021
Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancerMamta Parikh, Chengfei Liu, Chun-Yi Wu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 28, 2024
High-Temporal-Resolution Kinetic Modeling of Lung Tumors with Dual-Blood Input Function Using Total-Body Dynamic PETYiran Wang, Yasser G Abdelhafez, Benjamin A Spencer, et al.
Cancer|June 19, 2026
Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparibRana R McKay, Wanling Xie, Archana Ajmera, et al.
Biomedicines|May 27, 2026
Characterizing Response to PARP Inhibitor Treatment Combinations in Advanced Prostate CancerBryan Correa Gonzalez, Akshaya Karthikeyan, Love A Moore, et al.
Prostate Cancer and Prostatic Diseases|February 29, 2024
Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronelPrimo N Lara, Edward Mayerson, Erik Gertz, et al.
Nanomedicine (London, England)|June 2, 2026
A Phase I trial of PLZ4-coated paclitaxel-loaded micelles in patients with refractory non-muscle-invasive bladder cancerAthira Narayan, Ryan C Leibrandt, Joyce S Lee, et al.
Endocrine-Related Cancer|May 1, 2025
Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancerAlyssa Liang, Shuchi Gulati, Quillan Huang, et al.
Scientific Reports|June 14, 2023
Cisplatin-induced increase in heregulin 1 and its attenuation by the monoclonal ErbB3 antibody seribantumab in bladder cancerThomas M Steele, Maria Malvina Tsamouri, Salma Siddiqui, et al.
Molecular Cancer Therapeutics|December 5, 2025
IGFBP3-SphK1/S1P Signaling Axis Drives Enzalutamide Resistance in Advanced Prostate CancerAmy R Leslie, Shu Ning, Masuda Sharifi, et al.
Pageof 5